Literature DB >> 7722543

Measuring changes in logarithmic data, with special reference to bronchial responsiveness.

J K Peat1, W R Unger, D Combe.   

Abstract

Bronchial provocation tests with agents such as histamine and methacholine are commonly used in clinical and epidemiological studies of respiratory illness because bronchial hyperresponsiveness is a non-specific abnormality of the airways which is characteristic of asthma. However, measurements of bronchial responsiveness are log-normally distributed. As a result, special considerations need to be given to reporting within-subject changes in these measurements in longitudinal studies as, for example, in clinical trials or in any study in which a before-and-after experimental design is used. In these types of experiments, changes in bronchial responsiveness should not be simply expressed in the units of the measurement, such as dose of provoking agent, but must be expressed in units based on a logarithmic scale. The appropriate log-based units for measuring within-subject changes are doubling dose, fold difference or percent change. This paper explains the methods for calculating changes in these units in a statistically correct manner. All three units represent different ways of expressing the same change on a logarithmic scale. However, 'doubling dose' is only appropriate when it relates directly to the method of administering the provoking agent in doubling concentrations and 'fold difference' or 'percent change' are both appropriate for expressing any log-based changes. The methods for calculating changes in these units also apply to calculations of repeatability within test methods and to calculations of comparability and agreement between test methods. The methods are described solely for reporting changes in units of bronchial responsiveness but are applicable to other log-normally distributed measurements.

Entities:  

Mesh:

Year:  1994        PMID: 7722543     DOI: 10.1016/0895-4356(94)90096-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  9 in total

Review 1.  Methodology of bronchial responsiveness.

Authors:  S Chinn
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

2.  Comparing and combining studies of bronchial responsiveness.

Authors:  Susan Chinn
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

3.  Assessment of food chemical intolerance in adult asthmatic subjects.

Authors:  L Hodge; K Y Yan; R L Loblay
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

4.  Repeatability of bronchial hyperresponsiveness to adenosine-5'-monophosphate (AMP) by a short dosimeter protocol.

Authors:  G De Meer; D J Heederik; B Brunekreef; D S Postma
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

Review 5.  Reproducibility of non-specific bronchial challenge in adults: implications for design, analysis and interpretation of clinical and epidemiological studies.

Authors:  S Chinn; J P Schouten
Journal:  Thorax       Date:  2005-05       Impact factor: 9.139

6.  Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects.

Authors:  D W Evans; C M Salome; G G King; S J Rimmer; J P Seale; A J Woolcock
Journal:  Thorax       Date:  1997-02       Impact factor: 9.139

7.  Methacholine PC20 in African Americans and whites with asthma with homozygous genotypes at ADRB2 codon 16.

Authors:  Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima
Journal:  Pulm Pharmacol Ther       Date:  2013-02-04       Impact factor: 3.410

8.  Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responses.

Authors:  D R Brown; D J Fowell; D B Corry; T A Wynn; N H Moskowitz; A W Cheever; R M Locksley; S L Reiner
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

9.  Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

Authors:  D B Corry; H G Folkesson; M L Warnock; D J Erle; M A Matthay; J P Wiener-Kronish; R M Locksley
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.